To describe the clinical result of iris-claw intraocular lens (IOL) implantation in aphakic patients. A retrospective study of patients with the aphakic condition treated with iris-claw IOL implantation in dr. Saiful Anwar General hospital, Malang, Indonesia, from January 2019 until January 2021. Patient characteristics and clinical data, including age, gender, visual acuity pre and post-operative, retinometry, refractive error and correction, slit lamp biomicroscopy, and intraocular pressure, were recorded from clinical records. Fourteen eyes from fourteen patients with implantation iris-claw IOL were enrolled. The mean age was 55,85 (±12,84) years, with 64,28% males, and nine patients (64,28%) underwent right eye surgery. Uncorrected visual acuity in logmar from 1st day (1,053 ±0,543), 7th day (0,689 ±0,225), 14th day (0,508 ±0,202) and 30th day (0,410 ±0,225) after surgery is significantly better than before surgery (1,757 ±0,080). Best corrected visual acuity (BCVA) in logmar from 7th day (0,376 ±0,187), 14th day (0,235 ±0,200) and 30th day (0,208 ±0,211) after surgery is not significantly different from before surgery (0,312 ±0,224). Both results are not significantly different from result before surgery (0,467 ±0,362). Refractive correction after surgery (0,973 ±0,750) is better than before surgery (10,250 ±0,427), with 42,85% is myopic compound astigmatism. Corneal edema was found in 5 patients (35,71%), increased intraocular pressure (IOP) dan decrease (IOP) were found in 1 patient (7,14%), but all patients got better in 7th day post-operative. Uncorrected visual acuity is better after iris-claw IOL implantation, while BCVA is not significantly different. Iris-claw implantation is safe because of minimal complications.